Literature DB >> 18973741

Perimenstrual migraines: are they different from migraines in general?

Stewart J Tepper1.   

Abstract

Differences between menstrually related migraine (MRM) and non-MRM are subtle. Preconception that population-based trials do not show differences, but that clinic-based trials showed severe, longer, and clinically refractory menstrual migraines, turns out to be simplistic. This review examines studies comparing and contrasting MRM and non-MRM. All of the pertinent studies show increase of migraine around menses. A judicious reading of the studies suggests that MRM is probably more severe in pain intensity than non-MRM. MRM is more disabling than non-MRM. MRM in clinics is more likely to have both worse prodrome and nausea. A significant subset of MRM patients has poorer response to acute medication. Overall, it appears that MRM is more severe than non-MRM when considering population- and clinic-based studies, with slightly but clinically meaningfully worse intensity, duration, disability, prodrome, nausea, and response to acute medications. Clinicians must have compassion and skill to manage patients with MRM.

Entities:  

Mesh:

Year:  2008        PMID: 18973741     DOI: 10.1007/s11916-008-0078-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  18 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

Review 2.  Migraine associated with menstruation.

Authors:  A MacGregor
Journal:  Funct Neurol       Date:  2000

3.  Progesterone suppositories and pessaries in the treatment of menstrual migraine.

Authors:  K Dalton
Journal:  Headache       Date:  1973-01       Impact factor: 5.887

4.  Rizatriptan in the treatment of menstrual migraine.

Authors:  S D Silberstein; H Massiou; C Le Jeunne; L Johnson-Pratt; K A McCarroll; C R Lines
Journal:  Obstet Gynecol       Date:  2000-08       Impact factor: 7.661

5.  Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: a general practice study.

Authors:  Andrew J Dowson; Shaun G Kilminster; Rebecca Salt; Matthew Clark; Michael J Bundy
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

6.  Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.

Authors:  N T Mathew; M Asgharnejad; M Peykamian; A Laurenza
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

7.  Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura.

Authors:  L M Cupini; M Matteis; E Troisi; P Calabresi; G Bernardi; M Silvestrini
Journal:  Cephalalgia       Date:  1995-04       Impact factor: 6.292

8.  Prevalence of migraine on each day of the natural menstrual cycle.

Authors:  E Anne MacGregor; Allan Hackshaw
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

9.  Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study.

Authors:  Elizabeth Loder; Stephen D Silberstein; Susan Abu-Shakra; Loretta Mueller; Timothy Smith
Journal:  Headache       Date:  2004-02       Impact factor: 5.887

10.  Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan.

Authors:  M P Solbach; R S Waymer
Journal:  Obstet Gynecol       Date:  1993-11       Impact factor: 7.661

View more
  2 in total

1.  Burden of migraine related to menses: results from the AMPP study.

Authors:  Jelena M Pavlović; Walter F Stewart; Christa A Bruce; Jennifer A Gorman; Haiyan Sun; Dawn C Buse; Richard B Lipton
Journal:  J Headache Pain       Date:  2015-03-18       Impact factor: 7.277

2.  Mal de Debarquement Syndrome: A Retrospective Online Questionnaire on the Influences of Gonadal Hormones in Relation to Onset and Symptom Fluctuation.

Authors:  Viviana Mucci; Josephine M Canceri; Rachael Brown; Mingjia Dai; Sergei B Yakushin; Shaun Watson; Angelique Van Ombergen; Yves Jacquemyn; Paul Fahey; Paul H Van de Heyning; Floris Wuyts; Cherylea J Browne
Journal:  Front Neurol       Date:  2018-05-24       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.